Asia-Pacific Launches HGP2 Rare Disease Alliance to Bridge Diagnostic Gaps
Diagnosing a rare disease is often a grueling journey for patients, frequently involving years of uncertainty and multiple misdiagnoses. In a major move to shorten this “diagnostic odyssey,” the HGP2 Rare Disease Alliance of the Asia-Pacific Region (HGP2 RaDiAnce–APAC) was officially launched in Kuala Lumpur on May 10, 2026. This regional coalition aims to standardize genomic medicine and accelerate the identification of rare genetic conditions across the Asia-Pacific.
The alliance brings together members from 10 countries, operating under the framework of the Human Genome Project II (HGP2). By unifying resources and expertise, the initiative seeks to close the significant care gap that currently leaves millions of patients in the region without accurate diagnoses or personalized treatment plans.
A Unified Strategy for Genomic Medicine
The launch of HGP2 RaDiAnce–APAC isn’t just a symbolic gathering; it’s a structured effort to harmonize how rare diseases are handled across borders. During the inaugural meeting, alliance members signed a Joint Declaration that establishes a shared commitment to regional collaboration. This declaration focuses on five critical pillars designed to modernize rare disease care:
- Ethics: Ensuring genomic data is handled with strict privacy and moral standards.
- Accessibility: Making high-tech diagnostic tools available to underserved populations.
- Collaboration: Sharing data and research between the 10 member nations.
- Acceleration: Reducing the time it takes from the first symptom to a definitive diagnosis.
- Public Response: Improving how healthcare systems and governments respond to the needs of rare disease patients.
The Shift Toward Precision Health
A central theme of the alliance is the transition from “reactive” medicine—treating symptoms after they appear—to “precision health,” which uses a patient’s genetic makeup to predict and prevent illness. This shift is a priority for regional health leaders who see genomics as the cornerstone of future healthcare.
“Precision health is not a future ambition, but a present responsibility. In Malaysia, we are committed to moving from reactive care to predictive, preventive, and more personalized healthcare by integrating genomics, artificial intelligence, advanced technology, and strong policy frameworks into our health system.”
— YBhg. Datuk Dr. Nor Fariza Binti Ngah, Deputy Director-General of Health (Research and Technical Support) at the Ministry of Health of Malaysia
Closing the Gap with Advanced Genomics
The alliance leverages the technical capabilities of organizations like BGI Genomics to implement the tools necessary for large-scale genomic screening. By integrating artificial intelligence and advanced sequencing technology, the alliance intends to identify genetic markers that were previously undetectable, providing answers to families who have spent years searching for them.
Hou Yong, General Manager of BGI Genomics, joined other leading experts at the launch to discuss the urgent priorities of public health response and the necessity of integrating these technologies into existing national health frameworks.
Key Takeaways: HGP2 RaDiAnce–APAC
- Scope: A 10-country coalition focused on the Asia-Pacific region.
- Goal: To eliminate the diagnostic gap for rare diseases using the Human Genome Project II (HGP2) framework.
- Core Focus: Integration of AI, genomics, and policy to move toward predictive and personalized healthcare.
- Strategic Pillars: Ethics, accessibility, collaboration, acceleration, and public response.
Looking Ahead
The establishment of HGP2 RaDiAnce–APAC marks a pivot toward a more integrated healthcare model in Asia. As the alliance begins to implement its Joint Declaration, the focus will shift toward building the actual infrastructure—labs, data-sharing protocols, and trained personnel—needed to make precision health a reality for every citizen in the member states. If successful, this model could serve as a blueprint for other regions struggling to manage the complexities of rare genetic disorders.
